Technical Analysis for TCON - TRACON Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 0.96 -9.43% -0.10
TCON closed down 9.43 percent on Friday, January 18, 2019, on 1.75 times normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical TCON trend table...

Date Alert Name Type % Chg
Jan 18 50 DMA Resistance Bearish 0.00%
Jan 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Upper Bollinger Band Touch Strength 0.00%
Jan 17 50 DMA Resistance Bearish -9.43%
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -9.43%
Jan 17 Pocket Pivot Bullish Swing Setup -9.43%
Jan 17 Volume Surge Other -9.43%
Jan 17 Wide Bands Range Expansion -9.43%
Jan 17 Up 3 Days in a Row Strength -9.43%

Older signals for TCON ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration, and fibrotic diseases. Its lead product candidate is TRC105, which is in Phase II clinical trials for oncology indications, including soft tissue sarcoma, renal cell carcinoma, glioblastoma, and hepatocellular carcinoma. The company is planning for clinical trials of TRC105, including a Phase II clinical trial in patients with breast cancer and hepatocellular carcinoma, a Phase I clinical trial in patients with colorectal cancer, and a Phase I clinical trial in patients with lung cancer, as well as conducting preclinical studies of TRC105 in AMD. In addition, the company product candidates comprise TRC205, an anti-endoglin antibody that is in preclinical stage for the treatment of fibrotic diseases; and TRC102, a small molecule, which is in clinical development for the treatment of lung cancer and glioblastoma. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Is TCON a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.2
52 Week Low 0.5
Average Volume 318,577
200-Day Moving Average 2.0223
50-Day Moving Average 1.059
20-Day Moving Average 0.7815
10-Day Moving Average 0.869
Average True Range 0.1565
ADX 20.22
+DI 30.1283
-DI 14.9477
Chandelier Exit (Long, 3 ATRs ) 0.7305
Chandelier Exit (Short, 3 ATRs ) 0.9695
Upper Bollinger Band 1.0469
Lower Bollinger Band 0.5161
Percent B (%b) 0.84
BandWidth 67.920665
MACD Line -0.0315
MACD Signal Line -0.0806
MACD Histogram 0.0491
Fundamentals Value
Market Cap 15.99 Million
Num Shares 16.7 Million
EPS -1.75
Price-to-Earnings (P/E) Ratio -0.55
Price-to-Sales 17.03
Price-to-Book 2.65
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.31
Resistance 3 (R3) 1.33 1.23 1.25
Resistance 2 (R2) 1.23 1.15 1.22 1.23
Resistance 1 (R1) 1.10 1.09 1.05 1.08 1.21
Pivot Point 1.00 1.00 0.98 0.99 1.00
Support 1 (S1) 0.87 0.92 0.82 0.85 0.71
Support 2 (S2) 0.77 0.86 0.76 0.69
Support 3 (S3) 0.64 0.77 0.67
Support 4 (S4) 0.62